Industry: Pharmaceuticals, Biotechnology
has discovered a fundamental immune mechanism, by which the immune response to any disease-causing antigen may be suppressed while the vital normal function of the immune system as a whole is preserved. The Company, located in Cambridge, UK, is developing a pipeline of protein and DNA therapeutics for the treatment of immune disorders using its proprietary antigen-specific therapy (ASPECT™) platforms. This new class of targeted medicines has the potential to transform the treatment of a broad range of major immunological disorders, including allergy, autoimmune disease and transplant rejection.The multiple product potential of the ASPECT platforms allows Lorantis to pursue a balanced portfolio of internally developed products and out-licensed product development ( www.lorantis.co.uk )
Lorantis , Ltd.
410 Cambridge Science Park, Milton Road,
Cambridge, CB4 0WG
United Kingdom
Tel: +44 1223 702500
Fax: +44 1223 702599